+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID03138161

Phase 12 Study of Trabectedin with Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

Led by Sarcoma Oncology Research Center, LLC · Updated on 2025-02-24

250

Participants Needed

1

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and appropriate dosing of a combination of three drugsTrabectedin, Ipilimumab, and Nivolumabin adults with advanced soft tissue sarcoma who have received prior treatment. This phase 12 open-label study builds on earlier trial results to find the highest dose patients can safely tolerate and to assess safety and potential effectiveness in a larger group. During the dose escalation phase, small groups of patients receive increasing doses of Trabectedin intravenously every three weeks, alongside fixed doses of Ipilimumab every 12 weeks and Nivolumab every two weeks. The maximum tolerated dose is identified by monitoring for dose-limiting toxicities. In the expansion phase, more patients receive the identified safe dose of Trabectedin with the same fixed doses of the other two drugs. Some patients may undergo surgery after treatment cycles, and tissue samples will be analyzed to study the drugs effects. Participants attend regular visits for treatment and monitoring up to one year or until disease progression or unacceptable side effects. Assessments include scans, laboratory tests, and tissue analyses to evaluate response and immune activity in tumors. Researchers measure the maximum tolerated dose and monitor response rates, disease control, progression-free survival, and overall survival over 24 months. Safety and treatment effects are closely followed throughout the study.

CONDITIONS

Brief Title

SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

Research Team

E

Erlinda M Gordon, MD

V

Victoria Chua-Alcala, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here